

CITATION REPORT

List of articles citing

Sildenafil: a review of its use in pulmonary arterial hypertension

DOI: 10.2165/00003495-200868030-00009
Drugs, 2008, 68, 383-97.

Source: <https://exaly.com/paper-pdf/43859285/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
56	Ambrisentan. <i>Drugs</i> , 2008 , 68, 2195-204	12.1	33
55	Phosphodiesterase 5 inhibition blocks pressure overload-induced cardiac hypertrophy independent of the calcineurin pathway. <i>Cardiovascular Research</i> , 2009 , 81, 301-9	9.9	40
54	Sildenafil in Acute Pulmonary Embolism: Case Report and Review of Literature. <i>Journal of the Intensive Care Society</i> , 2009 , 10, 44-45	1.6	4
53	Pulmonary arterial hypertension in human immunodeficiency virus infection. <i>Postgraduate Medicine</i> , 2009 , 121, 56-67	3.7	7
52	Type 5 phosphodiesterase expression is a critical determinant of the endothelial cell angiogenic phenotype. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2009 , 296, L220-8	5.8	25
51	Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. <i>Pharmacology & Therapeutics</i> , 2009 , 122, 216-38	13.9	273
50	Cardiovascular effects of phosphodiesterase type 5 inhibitors. <i>Journal of Sexual Medicine</i> , 2009 , 6, 658-74	4.1	38
49	[Combination therapy for pulmonary arterial hypertension]. <i>Archivos De Bronconeumologia</i> , 2009 , 45, 36-40	0.7	1
48	Phosphatidylethanolamine-binding proteins, including RKIP, exhibit affinity for phosphodiesterase-5 inhibitors. <i>ChemBioChem</i> , 2009 , 10, 2654-62	3.8	11
47	Sildenafil for the treatment of pulmonary hypertension in pediatric patients. <i>Pediatric Cardiology</i> , 2009 , 30, 871-82	2.1	36
46	Substrate-specific pharmacokinetic interaction between endothelin receptor antagonists and phosphodiesterase-5 inhibitors--assembling the clues. <i>British Journal of Clinical Pharmacology</i> , 2009 , 67, 475-7	3.8	2
45	Molecular mechanisms of pulmonary hypertension. <i>Clinica Chimica Acta</i> , 2009 , 403, 9-16	6.2	38
44	Combination Therapy for Pulmonary Arterial Hypertension. <i>Archivos De Bronconeumologia</i> , 2009 , 45, 36-40	0.7	
43	Sildenafil's protective effect against cardiac hypertrophy. <i>Expert Review of Clinical Pharmacology</i> , 2009 , 2, 323-7	3.8	2
42	Leads for the treatment of pulmonary hypertension. <i>Expert Opinion on Therapeutic Patents</i> , 2009 , 19, 575-92	6.8	7
41	Tadalafil, a long-acting inhibitor of PDE5, improves pulmonary hemodynamics and survival rate of monocrotaline-induced pulmonary artery hypertension in rats. <i>Journal of Pharmacological Sciences</i> , 2009 , 111, 235-43	3.7	40
40	Phosphodiesterase Inhibitors in Vascular Ischemia: A Case Report and Review of Their Use in Ischemic Conditions. <i>Canadian Journal of Plastic Surgery</i> , 2010 , 18, 5-9		5

39	Should we administer sildenafil to patients with acute respiratory distress syndrome? No. <i>Intensive Care Medicine</i> , 2010 , 36, 1102-3; author reply 1104-5	14.5	
38	A gas chromatography/mass spectrometry method for the determination of sildenafil, vardenafil and tadalafil and their metabolites in human urine. <i>Rapid Communications in Mass Spectrometry</i> , 2010 , 24, 1697-706	2.2	44
37	Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: safety, tolerability, and efficacy. <i>Drug, Healthcare and Patient Safety</i> , 2010 , 2, 151-61	1.6	18
36	Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension. <i>Future Cardiology</i> , 2010 , 6, 19-35	1.3	17
35	Ambrisentan. <i>American Journal of Cardiovascular Drugs</i> , 2011 , 11, 215-26	4	33
34	Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study. <i>Journal of Clinical Pharmacology</i> , 2011 , 51, 1051-60	2.9	38
33	The GAF-tandem domain of phosphodiesterase 5 as a potential drug target. <i>Handbook of Experimental Pharmacology</i> , 2011 , 151-66	3.2	10
32	High-performance liquid chromatographic method with amperometric detection employing boron-doped diamond electrode for the determination of sildenafil, vardenafil and their main metabolites in plasma. <i>Journal of Chromatography A</i> , 2011 , 1218, 7996-8001	4.5	20
31	Medication Repurposing: New Uses for Old Drugs. <i>Journal of Pharmacy Technology</i> , 2011 , 27, 132-140	0.6	5
30	Pharmacokinetic evaluation of ambrisentan. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011 , 7, 371-80	5.5	14
29	The ability of phosphodiesterase-5 inhibitors sildenafil and ordonafil to reverse L-NAME induced cardiac hypertrophy in the rabbit: possible role of calcineurin and p38. <i>Canadian Journal of Physiology and Pharmacology</i> , 2012 , 90, 1247-55	2.4	5
28	Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. <i>British Journal of Pharmacology</i> , 2012 , 165, 1288-305	8.6	224
27	Sildenafil potentiates bone morphogenetic protein signaling in pulmonary arterial smooth muscle cells and in experimental pulmonary hypertension. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013 , 33, 34-42	9.4	55
26	Combination pharmacotherapy in the treatment of pulmonary arterial hypertension: continuing education article. <i>Journal of Pharmacy Practice</i> , 2013 , 26, 18-28	1.3	2
25	Drug monographs. 2014 , 57-553		
24	Changes in the pharmacokinetic of sildenafil citrate in rats with Streptozotocin-induced diabetic nephropathy. <i>Journal of Diabetes and Metabolic Disorders</i> , 2014 , 13, 8	2.5	9
23	Pharmacologic therapy that simulates conditioning for cardiac ischemic/reperfusion injury. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014 , 19, 83-96	2.6	62
22	Evaluation of PET radioligands for in vivo visualization of phosphodiesterase 5 (PDE5). <i>Nuclear Medicine and Biology</i> , 2014 , 41, 155-62	2.1	14

21	Clinical and molecular genetics of the phosphodiesterases (PDEs). <i>Endocrine Reviews</i> , 2014 , 35, 195-233	27.2	157
20	The adrenergic system in pulmonary arterial hypertension: bench to bedside (2013 Grover Conference series). <i>Pulmonary Circulation</i> , 2015 , 5, 415-23	2.7	14
19	Extending the translational potential of targeting NO/cGMP-regulated pathways in the CVS. <i>British Journal of Pharmacology</i> , 2015 , 172, 1397-414	8.6	21
18	[Cardioprotection in cardiac surgical patients : Everything good comes from the heart]. <i>Der Anaesthetist</i> , 2016 , 65, 169-82	2.2	3
17	BMP type II receptor as a therapeutic target in pulmonary arterial hypertension. <i>Cellular and Molecular Life Sciences</i> , 2017 , 74, 2979-2995	10.3	54
16	Carbon-11 and Fluorine-18 Radiolabeled Pyridopyrazinone Derivatives for Positron Emission Tomography (PET) Imaging of Phosphodiesterase-5 (PDE5). <i>Journal of Medicinal Chemistry</i> , 2017 , 60, 486-496	8.3	5
15	Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure. <i>British Journal of Pharmacology</i> , 2018 , 175, 223-231	8.6	21
14	Sildenafil Reduces Neointimal Hyperplasia after Angioplasty and Inhibits Platelet Aggregation via Activation of cGMP-dependent Protein Kinase. <i>Scientific Reports</i> , 2019 , 9, 7769	4.9	15
13	Efficiency of sildenafil encapsulation in poloxamer micelles. <i>Journal of Dispersion Science and Technology</i> , 2019 , 40, 1461-1468	1.5	3
12	Oral drugs used to treat persistent pulmonary hypertension of the newborn. <i>Expert Review of Clinical Pharmacology</i> , 2020 , 13, 1295-1308	3.8	3
11	[Off-label therapies in oncology]. <i>Orvosi Hetilap</i> , 2009 , 150, 363-72	0.8	
10	Part Introduction. 33-280		
9	Selective Pulmonary Vasodilators. 2015 , 809-836		
8	Effect of Sildenafil Citrate on Exercise Capacity in Athletes With Spinal Cord Injury. <i>International Journal of Sports Physiology and Performance</i> , 2020 , 1-5	3.5	1
7	Phosphodiesterase inhibitors in vascular ischemia: A case report and review of their use in ischemic conditions. <i>Canadian Journal of Plastic Surgery</i> , 2010 , 18, e5-9		2
6	Additive effect of phosphodiesterase inhibitors in control of pulmonary hypertension after congenital cardiac surgery in children. <i>Iranian Journal of Pediatrics</i> , 2013 , 23, 19-26	1	9
5	Pulmonary Arterial Hypertension-A Deadly Complication of Systemic Sclerosis. 2010 , 1, 11-20		
4	Transfer of human hepatocyte growth factor reduces inflammation and prevents pulmonary arterial remodeling in monocrotaline-induced. <i>International Journal of Clinical and Experimental Pathology</i> , 2014 , 7, 8763-9	1.4	4

3	A Review on Phosphodiesterase-5 Inhibitors as a Topical Therapy for Erectile Dysfunction.. <i>Sexual Medicine Reviews</i> , 2022 ,	5.6	1
2	Combination of Sildenafil and Ba at a Low Concentration Show a Significant Synergistic Inhibition of Inward Rectifier Potassium Current Resulting in Action Potential Prolongation.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 829952	5.6	0
1	Development and characterization of nanodispersion-based sildenafil pressurized metered-dose inhaler using combined small-angle X-ray scattering, dynamic light scattering, and impactors. 2022 , 76, 103749		1